Statera Biopharma, Lay Sciences announce intent to enter strategic partnership

Image: Lay Sciences would have the potential to receive royalties and milestones related to the development of IgY in gastrointestinal and upper respiratory indications. Credit: Martin Büdenbender from Pixabay.